SCHEMBL1099396

SCHEMBL1099396

COc1cc(N=C=O)ccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.42
ALDH1A1 P00352 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
HPGD P15428 2/20 0.42
TRPA1 O75762 1/20 0.41
MAPK1 P28482 1/20 0.40
HTR2A P28223 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.37
HTR2C P28335 1/20 0.36
KDM4E B2RXH2 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
PTGS2 P35354 2/20 0.35
PTGS1 P23219 1/20 0.35
AR P10275 4/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472171 1.00 CYP3A4 (0.42) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL1091015 0.87 CYP3A4 (0.42) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL29600721 0.79 HTR3E (0.53) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL1555041 0.79 MAPK1 (0.47) CYP3A4TDP1TRPA1MAPK1TSHR
SCHEMBL307695 0.79 HTR3E (0.53) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL15987971 0.78 CYP3A4 (0.46) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL893938 0.78 CYP3A4 (0.49) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL543088 0.76 CYP3A4 (0.71) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL29800238 0.76 CYP3A4 (0.71) CYP3A4ALDH1A1TDP1HPGDTRPA1
SCHEMBL30196175 0.76 KIF11 (0.45) CYP3A4TDP1TRPA1MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393781-B1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-8153809-B2 Dihydropyridone ureas as P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-04-10 US disclosed
EP-2393781-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS F. Hoffmann-La Roche AG (CH) 2011-12-14 EP disclosed
WO-2010072599-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS P2RY1, P2RX1, P2RX3 CYP3A4 1966/4885ALDH1A1 1399/4885TDP1 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.